This study sets out to investigate if the S-acylation of CD36 is a driving force for metabolic and contractile dysfunction in the diabetic heart and, critically, if pharmacologically targeting the S-acylation enzymes can reverse dysfunction in diabetes. The gene discussed is CD36; the disease is diabetes mellitus.